Search

Your search keyword '"Pettitt, Stephen"' showing total 530 results
Start Over Author "Pettitt, Stephen"
530 results on '"Pettitt, Stephen"'

5. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

Author

Zelceski, Anabel, Francica, Paola, Lingg, Lea, Mutlu, Merve, Stok, Colin, Liptay, Martin, Alexander, John, Baxter, Joseph S., Brough, Rachel, Gulati, Aditi, Haider, Syed, Raghunandan, Maya, Song, Feifei, Sridhar, Sandhya, Forment, Josep V., O’Connor, Mark J., Davies, Barry R., van Vugt, Marcel A.T.M., Krastev, Dragomir B., Pettitt, Stephen J., Tutt, Andrew N.J., Rottenberg, Sven, and Lord, Christopher J.

Published
2023
Full Text
View/download PDF

7. Abstract PR010: CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality

Author

Tien, Jean C., primary, Chang, Yu, additional, Zhang, Yuping, additional, Chou, Jonathan, additional, Cheng, Yunhui, additional, Wang, Xiaoju, additional, Yang, Jianzhang, additional, Mannan, Rahul, additional, Shah, Palak, additional, Wang, Xiao-Ming, additional, Todd, Abbey, additional, Eyunni, Sanjana, additional, Cheng, Caleb, additional, Cao, Xuhong, additional, Bao, Yi, additional, Neiswender, James, additional, Brough, Rachel, additional, Pettitt, Stephen, additional, Labanca, Estefania, additional, Wang, Yuzhuo, additional, Cieslik, Marcin, additional, Lord, Christopher J., additional, Ding, Ke, additional, and Chinnaiyan, Arul M., additional

Published
2024
Full Text
View/download PDF

9. E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

Author

Bajrami, Ilirjana, Marlow, Rebecca, van de Ven, Marieke, Brough, Rachel, Pemberton, Helen N, Frankum, Jessica, Song, Feifei, Rafiq, Rumana, Konde, Asha, Krastev, Dragomir B, Menon, Malini, Campbell, James, Gulati, Aditi, Kumar, Rahul, Pettitt, Stephen J, Gurden, Mark D, Cardenosa, Marta Llorca, Chong, Irene, Gazinska, Patrycja, Wallberg, Fredrik, Sawyer, Elinor J, Martin, Lesley-Ann, Dowsett, Mitch, Linardopoulos, Spiros, Natrajan, Rachael, Ryan, Colm J, Derksen, Patrick WB, Jonkers, Jos, Tutt, Andrew NJ, Ashworth, Alan, and Lord, Christopher J

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Cancer, Brain Disorders, Breast Cancer, Good Health and Well Being, Anilides, Animals, Antigens, CD, Antineoplastic Agents, Breast Neoplasms, Cadherins, Cell Line, Tumor, Crizotinib, Female, Humans, Mice, Mutation, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Quinolines, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered CDH1 mutations, we identified synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic screens in molecularly diverse breast tumor cell lines established that the E-cadherin/ROS1 synthetic lethality was not only robust in the face of considerable molecular heterogeneity but was also elicited with clinical ROS1 inhibitors, including foretinib and crizotinib. ROS1 inhibitors induced mitotic abnormalities and multinucleation in E-cadherin-defective cells, phenotypes associated with a defect in cytokinesis and aberrant p120 catenin phosphorylation and localization. In vivo, ROS1 inhibitors produced profound antitumor effects in multiple models of E-cadherin-defective breast cancer. These data therefore provide the preclinical rationale for assessing ROS1 inhibitors, such as the licensed drug crizotinib, in appropriately stratified patients.Significance: E-cadherin defects are common in breast cancer but are currently not targeted with a precision medicine approach. Our preclinical data indicate that licensed ROS1 inhibitors, including crizotinib, should be repurposed to target E-cadherin-defective breast cancers, thus providing the rationale for the assessment of these agents in molecularly stratified phase II clinical trials. Cancer Discov; 8(4); 498-515. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 371.

Published
2018

11. Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.

Author

Pettitt, Stephen J, Krastev, Dragomir B, Pemberton, Helen N, Fontebasso, Yari, Frankum, Jessica, Rehman, Farah L, Brough, Rachel, Song, Feifei, Bajrami, Ilirjana, Rafiq, Rumana, Wallberg, Fredrik, Kozarewa, Iwanka, Fenwick, Kerry, Armisen-Garrido, Javier, Swain, Amanda, Gulati, Aditi, Campbell, James, Ashworth, Alan, and Lord, Christopher J

Subjects
Animals, Mice, Neoplasms, DNA Transposable Elements, Antineoplastic Agents, Haploidy, Genome-Wide Association Study, Mouse Embryonic Stem Cells
Abstract

We describe a screen for cellular response to drugs that makes use of haploid embryonic stem cells. We generated ten libraries of mutants with piggyBac gene trap transposon integrations, totalling approximately 100,000 mutant clones. Random barcode sequences were inserted into the transposon vector to allow the number of cells bearing each insertion to be measured by amplifying and sequencing the barcodes. These barcodes were associated with their integration sites by inverse PCR. We exposed these libraries to commonly used cancer drugs and profiled changes in barcode abundance by Ion Torrent sequencing in order to identify mutations that conferred sensitivity. Drugs tested included conventional chemotherapeutics as well as targeted inhibitors of topoisomerases, poly(ADP-ribose) polymerase (PARP), Hsp90 and WEE1.

Published
2017

12. PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-κB-regulated immune response

Author

Kyula-Currie, Joan, primary, Roulstone, Victoria, additional, Wright, James, additional, Butera, Francesca, additional, Legrand, Arnaud, additional, Elliott, Richard, additional, McLaughlin, Martin, additional, Bozhanova, Galabina, additional, Krastev, Dragomir, additional, Pettitt, Stephen, additional, Tenev, Tencho, additional, Dillon, Magnus, additional, Foo, Shane, additional, Patin, Emmanuel, additional, Jennings, Victoria, additional, Chan, Charleen, additional, Appleton, Elizabeth, additional, Pedersen, Malin, additional, Rullan, Antonio, additional, Choudhary, Jyoti, additional, Bakal, Chris, additional, Meier, Pascal, additional, Lord, Christopher J, additional, Melcher, Alan, additional, and Harrington, Kevin, additional

Published
2023
Full Text
View/download PDF

13. Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7

Author

Baxter, Joseph S., primary, Brough, Rachel, additional, Krastev, Dragomir B., additional, Song, Feifei, additional, Sridhar, Sandhya, additional, Gulati, Aditi, additional, Alexander, John, additional, Roumeliotis, Theodoros I., additional, Kozik, Zuza, additional, Choudhary, Jyoti S., additional, Haider, Syed, additional, Pettitt, Stephen J., additional, Tutt, Andrew N. J., additional, and Lord, Christopher J., additional

Published
2023
Full Text
View/download PDF

15. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Author

Zatreanu, Diana, Robinson, Helen M. R., Alkhatib, Omar, Boursier, Marie, Finch, Harry, Geo, Lerin, Grande, Diego, Grinkevich, Vera, Heald, Robert A., Langdon, Sophie, Majithiya, Jayesh, McWhirter, Claire, Martin, Niall M. B., Moore, Shaun, Neves, Joana, Rajendra, Eeson, Ranzani, Marco, Schaedler, Theresia, Stockley, Martin, Wiggins, Kimberley, Brough, Rachel, Sridhar, Sandhya, Gulati, Aditi, Shao, Nan, Badder, Luned M., Novo, Daniela, Knight, Eleanor G., Marlow, Rebecca, Haider, Syed, Callen, Elsa, Hewitt, Graeme, Schimmel, Joost, Prevo, Remko, Alli, Christina, Ferdinand, Amanda, Bell, Cameron, Blencowe, Peter, Bot, Chris, Calder, Mathew, Charles, Mark, Curry, Jayne, Ekwuru, Tennyson, Ewings, Katherine, Krajewski, Wojciech, MacDonald, Ellen, McCarron, Hollie, Pang, Leon, Pedder, Chris, Rigoreau, Laurent, Swarbrick, Martin, Wheatley, Ed, Willis, Simon, Wong, Ai Ching, Nussenzweig, Andre, Tijsterman, Marcel, Tutt, Andrew, Boulton, Simon J., Higgins, Geoff S., Pettitt, Stephen J., Smith, Graeme C. M., and Lord, Christopher J.

Published
2021
Full Text
View/download PDF

16. Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.

Author

Baxter, Joseph S., Brough, Rachel, Krastev, Dragomir B., Song, Feifei, Sridhar, Sandhya, Gulati, Aditi, Alexander, John, Roumeliotis, Theodoros I., Kozik, Zuza, Choudhary, Jyoti S., Haider, Syed, Pettitt, Stephen J., Tutt, Andrew N. J., and Lord, Christopher J.

Abstract

The F‐box and WD repeat domain containing 7 (FBXW7) tumour suppressor gene encodes a substrate‐recognition subunit of Skp, cullin, F‐box (SCF)‐containing complexes. The tumour‐suppressive role of FBXW7 is ascribed to its ability to drive ubiquitination and degradation of oncoproteins. Despite this molecular understanding, therapeutic approaches that target defective FBXW7 have not been identified. Using genome‐wide clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 screens, focussed RNA‐interference screens and whole and phospho‐proteome mass spectrometry profiling in multiple FBXW7 wild‐type and defective isogenic cell lines, we identified a number of FBXW7 synthetic lethal targets, including proteins involved in the response to replication fork stress and proteins involved in replication origin firing, such as cell division cycle 7‐related protein kinase (CDC7) and its substrate, DNA replication complex GINS protein SLD5 (GINS4). The CDC7 synthetic lethal effect was confirmed using small‐molecule inhibitors. Mechanistically, FBXW7/CDC7 synthetic lethality is dependent upon the replication factor telomere‐associated protein RIF1 (RIF1), with RIF1 silencing reversing the FBXW7‐selective effects of CDC7 inhibition. The delineation of FBXW7 synthetic lethal effects we describe here could serve as the starting point for subsequent drug discovery and/or development in this area. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Agouti C57BL/6N embryonic stem cells for mouse genetic resources

Author

Pettitt, Stephen J, Liang, Qi, Rairdan, Xin Y, Moran, Jennifer L, Prosser, Haydn M, Beier, David R, Lloyd, Kent C, Bradley, Allan, and Skarnes, William C

Subjects
Biological Sciences, Genetics, Generic health relevance, Agouti Signaling Protein, Animals, Base Sequence, Cell Line, Crosses, Genetic, DNA Primers, Embryonic Stem Cells, Female, Gene Targeting, Genetic Techniques, Germ-Line Mutation, Hair Color, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Mutant Strains, Mice, Transgenic, Polymorphism, Single Nucleotide, Pregnancy, Transplantation Chimera, Technology, Medical and Health Sciences, Developmental Biology, Biological sciences
Abstract

We report the characterization of a highly germline competent C57BL/6N mouse embryonic stem cell line, JM8. To simplify breeding schemes, the dominant agouti coat color gene was restored in JM8 cells by targeted repair of the C57BL/6 nonagouti mutation. These cells provide a robust foundation for large-scale mouse knockout programs that aim to provide a public resource of targeted mutations in the C57BL/6 genetic background.

Published
2009

20. Abstract 6603: BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy

Author

Yen, Jennifer, primary, Chen, Sai, additional, Jenkins, Colby, additional, Overstreet, Brooke, additional, Fu, Yu, additional, Zhao, Jun, additional, Jiang, Tingting, additional, Drusbosky, Leylah, additional, Pettitt, Stephen, additional, Dorschner, Michael, additional, Lawrence, Lauren, additional, Chuang, Han-Yu, additional, and Tutt, Andrew, additional

Published
2023
Full Text
View/download PDF

21. Abstract 6094: Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy

Author

Harvey-Jones, Elizabeth, primary, Raghunandan, Maya, additional, Robbez-Masson, Luisa, additional, Thanussuyah, Alaguthurai, additional, Liccardo, Roberta, additional, Yablonovitch, Arielle, additional, Cai, Mingyang, additional, Drusbosky, Leylah, additional, Dorschner, Michael, additional, Pardo, Lorena Magraner, additional, Marlow, Rebecca, additional, Konde, Asha, additional, Trendell, Jennifer, additional, Alexander, John, additional, Haider, Syed, additional, Starling, Chris, additional, Roxanis, Ioannis, additional, Yen, Jennifer, additional, Pettitt, Stephen J., additional, Lord, Christopher J., additional, and Tutt, Andrew N., additional

Published
2023
Full Text
View/download PDF

23. Data from E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

Author

Bajrami, Ilirjana, primary, Marlow, Rebecca, primary, van de Ven, Marieke, primary, Brough, Rachel, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Song, Feifei, primary, Rafiq, Rumana, primary, Konde, Asha, primary, Krastev, Dragomir B., primary, Menon, Malini, primary, Campbell, James, primary, Gulati, Aditi, primary, Kumar, Rahul, primary, Pettitt, Stephen J., primary, Gurden, Mark D., primary, Cardenosa, Marta Llorca, primary, Chong, Irene, primary, Gazinska, Patrycja, primary, Wallberg, Fredrik, primary, Sawyer, Elinor J., primary, Martin, Lesley-Ann, primary, Dowsett, Mitch, primary, Linardopoulos, Spiros, primary, Natrajan, Rachael, primary, Ryan, Colm J., primary, Derksen, Patrick W.B., primary, Jonkers, Jos, primary, Tutt, Andrew N.J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 2 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Author

Dréan, Amy, primary, Williamson, Chris T., primary, Brough, Rachel, primary, Brandsma, Inger, primary, Menon, Malini, primary, Konde, Asha, primary, Garcia-Murillas, Isaac, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Rafiq, Rumana, primary, Badham, Nicholas, primary, Campbell, James, primary, Gulati, Aditi, primary, Turner, Nicholas C., primary, Pettitt, Stephen J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

25. Data from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Author

Dréan, Amy, primary, Williamson, Chris T., primary, Brough, Rachel, primary, Brandsma, Inger, primary, Menon, Malini, primary, Konde, Asha, primary, Garcia-Murillas, Isaac, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Rafiq, Rumana, primary, Badham, Nicholas, primary, Campbell, James, primary, Gulati, Aditi, primary, Turner, Nicholas C., primary, Pettitt, Stephen J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

28. Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

Author

Yap, Timothy A., primary, Kristeleit, Rebecca, primary, Michalarea, Vasiliki, primary, Pettitt, Stephen J., primary, Lim, Joline S.J., primary, Carreira, Suzanne, primary, Roda, Desamparados, primary, Miller, Rowan, primary, Riisnaes, Ruth, primary, Miranda, Susana, primary, Figueiredo, Ines, primary, Rodrigues, Daniel Nava, primary, Ward, Sarah, primary, Matthews, Ruth, primary, Parmar, Mona, primary, Turner, Alison, primary, Tunariu, Nina, primary, Chopra, Neha, primary, Gevensleben, Heidrun, primary, Turner, Nicholas C., primary, Ruddle, Ruth, primary, Raynaud, Florence I., primary, Decordova, Shaun, primary, Swales, Karen E., primary, Finneran, Laura, primary, Hall, Emma, primary, Rugman, Paul, primary, Lindemann, Justin P.O., primary, Foxley, Andrew, primary, Lord, Christopher J., primary, Banerji, Udai, primary, Plummer, Ruth, primary, Basu, Bristi, primary, Lopez, Juanita S., primary, Drew, Yvette, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Video S1 from E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

Author

Bajrami, Ilirjana, primary, Marlow, Rebecca, primary, van de Ven, Marieke, primary, Brough, Rachel, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Song, Feifei, primary, Rafiq, Rumana, primary, Konde, Asha, primary, Krastev, Dragomir B., primary, Menon, Malini, primary, Campbell, James, primary, Gulati, Aditi, primary, Kumar, Rahul, primary, Pettitt, Stephen J., primary, Gurden, Mark D., primary, Cardenosa, Marta Llorca, primary, Chong, Irene, primary, Gazinska, Patrycja, primary, Wallberg, Fredrik, primary, Sawyer, Elinor J., primary, Martin, Lesley-Ann, primary, Dowsett, Mitch, primary, Linardopoulos, Spiros, primary, Natrajan, Rachael, primary, Ryan, Colm J., primary, Derksen, Patrick W.B., primary, Jonkers, Jos, primary, Tutt, Andrew N.J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

Author

Yap, Timothy A., primary, Kristeleit, Rebecca, primary, Michalarea, Vasiliki, primary, Pettitt, Stephen J., primary, Lim, Joline S.J., primary, Carreira, Suzanne, primary, Roda, Desamparados, primary, Miller, Rowan, primary, Riisnaes, Ruth, primary, Miranda, Susana, primary, Figueiredo, Ines, primary, Rodrigues, Daniel Nava, primary, Ward, Sarah, primary, Matthews, Ruth, primary, Parmar, Mona, primary, Turner, Alison, primary, Tunariu, Nina, primary, Chopra, Neha, primary, Gevensleben, Heidrun, primary, Turner, Nicholas C., primary, Ruddle, Ruth, primary, Raynaud, Florence I., primary, Decordova, Shaun, primary, Swales, Karen E., primary, Finneran, Laura, primary, Hall, Emma, primary, Rugman, Paul, primary, Lindemann, Justin P.O., primary, Foxley, Andrew, primary, Lord, Christopher J., primary, Banerji, Udai, primary, Plummer, Ruth, primary, Basu, Bristi, primary, Lopez, Juanita S., primary, Drew, Yvette, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figures 1-10 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Author

Dréan, Amy, primary, Williamson, Chris T., primary, Brough, Rachel, primary, Brandsma, Inger, primary, Menon, Malini, primary, Konde, Asha, primary, Garcia-Murillas, Isaac, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Rafiq, Rumana, primary, Badham, Nicholas, primary, Campbell, James, primary, Gulati, Aditi, primary, Turner, Nicholas C., primary, Pettitt, Stephen J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 1 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Author

Dréan, Amy, primary, Williamson, Chris T., primary, Brough, Rachel, primary, Brandsma, Inger, primary, Menon, Malini, primary, Konde, Asha, primary, Garcia-Murillas, Isaac, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Rafiq, Rumana, primary, Badham, Nicholas, primary, Campbell, James, primary, Gulati, Aditi, primary, Turner, Nicholas C., primary, Pettitt, Stephen J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Information from E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

Author

Bajrami, Ilirjana, primary, Marlow, Rebecca, primary, van de Ven, Marieke, primary, Brough, Rachel, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Song, Feifei, primary, Rafiq, Rumana, primary, Konde, Asha, primary, Krastev, Dragomir B., primary, Menon, Malini, primary, Campbell, James, primary, Gulati, Aditi, primary, Kumar, Rahul, primary, Pettitt, Stephen J., primary, Gurden, Mark D., primary, Cardenosa, Marta Llorca, primary, Chong, Irene, primary, Gazinska, Patrycja, primary, Wallberg, Fredrik, primary, Sawyer, Elinor J., primary, Martin, Lesley-Ann, primary, Dowsett, Mitch, primary, Linardopoulos, Spiros, primary, Natrajan, Rachael, primary, Ryan, Colm J., primary, Derksen, Patrick W.B., primary, Jonkers, Jos, primary, Tutt, Andrew N.J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures S1-S20 from E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

Author

Bajrami, Ilirjana, primary, Marlow, Rebecca, primary, van de Ven, Marieke, primary, Brough, Rachel, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Song, Feifei, primary, Rafiq, Rumana, primary, Konde, Asha, primary, Krastev, Dragomir B., primary, Menon, Malini, primary, Campbell, James, primary, Gulati, Aditi, primary, Kumar, Rahul, primary, Pettitt, Stephen J., primary, Gurden, Mark D., primary, Cardenosa, Marta Llorca, primary, Chong, Irene, primary, Gazinska, Patrycja, primary, Wallberg, Fredrik, primary, Sawyer, Elinor J., primary, Martin, Lesley-Ann, primary, Dowsett, Mitch, primary, Linardopoulos, Spiros, primary, Natrajan, Rachael, primary, Ryan, Colm J., primary, Derksen, Patrick W.B., primary, Jonkers, Jos, primary, Tutt, Andrew N.J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Tables S1-S11 from E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

Author

Bajrami, Ilirjana, primary, Marlow, Rebecca, primary, van de Ven, Marieke, primary, Brough, Rachel, primary, Pemberton, Helen N., primary, Frankum, Jessica, primary, Song, Feifei, primary, Rafiq, Rumana, primary, Konde, Asha, primary, Krastev, Dragomir B., primary, Menon, Malini, primary, Campbell, James, primary, Gulati, Aditi, primary, Kumar, Rahul, primary, Pettitt, Stephen J., primary, Gurden, Mark D., primary, Cardenosa, Marta Llorca, primary, Chong, Irene, primary, Gazinska, Patrycja, primary, Wallberg, Fredrik, primary, Sawyer, Elinor J., primary, Martin, Lesley-Ann, primary, Dowsett, Mitch, primary, Linardopoulos, Spiros, primary, Natrajan, Rachael, primary, Ryan, Colm J., primary, Derksen, Patrick W.B., primary, Jonkers, Jos, primary, Tutt, Andrew N.J., primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Author

Serra, Violeta, primary, Wang, Anderson T., primary, Castroviejo-Bermejo, Marta, primary, Polanska, Urszula M., primary, Palafox, Marta, primary, Herencia-Ropero, Andrea, primary, Jones, Gemma N., primary, Lai, Zhongwu, primary, Armenia, Joshua, primary, Michopoulos, Filippos, primary, Llop-Guevara, Alba, primary, Brough, Rachel, primary, Gulati, Aditi, primary, Pettitt, Stephen J., primary, Bulusu, Krishna C., primary, Nikkilä, Jenni, primary, Wilson, Zena, primary, Hughes, Adina, primary, Wijnhoven, Paul W.G., primary, Ahmed, Ambar, primary, Bruna, Alejandra, primary, Gris-Oliver, Albert, primary, Guzman, Marta, primary, Rodríguez, Olga, primary, Grueso, Judit, primary, Arribas, Joaquin, primary, Cortés, Javier, primary, Saura, Cristina, primary, Lau, Alan, primary, Critchlow, Susan, primary, Dougherty, Brian, primary, Caldas, Carlos, primary, Mills, Gordon B., primary, Barrett, J. Carl, primary, Forment, Josep V., primary, Cadogan, Elaine, primary, Lord, Christopher J., primary, Cruz, Cristina, primary, Balmaña, Judith, primary, and O'Connor, Mark J., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Author

Serra, Violeta, primary, Wang, Anderson T., primary, Castroviejo-Bermejo, Marta, primary, Polanska, Urszula M., primary, Palafox, Marta, primary, Herencia-Ropero, Andrea, primary, Jones, Gemma N., primary, Lai, Zhongwu, primary, Armenia, Joshua, primary, Michopoulos, Filippos, primary, Llop-Guevara, Alba, primary, Brough, Rachel, primary, Gulati, Aditi, primary, Pettitt, Stephen J., primary, Bulusu, Krishna C., primary, Nikkilä, Jenni, primary, Wilson, Zena, primary, Hughes, Adina, primary, Wijnhoven, Paul W.G., primary, Ahmed, Ambar, primary, Bruna, Alejandra, primary, Gris-Oliver, Albert, primary, Guzman, Marta, primary, Rodríguez, Olga, primary, Grueso, Judit, primary, Arribas, Joaquin, primary, Cortés, Javier, primary, Saura, Cristina, primary, Lau, Alan, primary, Critchlow, Susan, primary, Dougherty, Brian, primary, Caldas, Carlos, primary, Mills, Gordon B., primary, Barrett, J. Carl, primary, Forment, Josep V., primary, Cadogan, Elaine, primary, Lord, Christopher J., primary, Cruz, Cristina, primary, Balmaña, Judith, primary, and O'Connor, Mark J., primary

Published
2023
Full Text
View/download PDF

44. The shieldin complex mediates 53BP1-dependent DNA repair

Author

Noordermeer, Sylvie M., Adam, Salomé, Setiaputra, Dheva, Barazas, Marco, Pettitt, Stephen J., Ling, Alexanda K., Olivieri, Michele, Álvarez-Quilón, Alejandro, Moatti, Nathalie, Zimmermann, Michal, Annunziato, Stefano, Krastev, Dragomir B., Song, Feifei, Brandsma, Inger, Frankum, Jessica, Brough, Rachel, Sherker, Alana, Landry, Sébastien, Szilard, Rachel K., Munro, Meagan M., McEwan, Andrea, Goullet de Rugy, Théo, Lin, Zhen-Yuan, Hart, Traver, Moffat, Jason, Gingras, Anne-Claude, Martin, Alberto, van Attikum, Haico, Jonkers, Jos, Lord, Christopher J., Rottenberg, Sven, and Durocher, Daniel

Published
2018
Full Text
View/download PDF

45. Supplementary Table 1 from ATR Is a Therapeutic Target in Synovial Sarcoma

Author

Jones, Samuel E., primary, Fleuren, Emmy D.G., primary, Frankum, Jessica, primary, Konde, Asha, primary, Williamson, Chris T., primary, Krastev, Dragomir B., primary, Pemberton, Helen N., primary, Campbell, James, primary, Gulati, Aditi, primary, Elliott, Richard, primary, Menon, Malini, primary, Selfe, Joanna L., primary, Brough, Rachel, primary, Pettitt, Stephen J., primary, Niedzwiedz, Wojciech, primary, van der Graaf, Winette T.A., primary, Shipley, Janet, primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

46. Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

Author

Chabanon, Roman M., primary, Morel, Daphné, primary, Eychenne, Thomas, primary, Colmet-Daage, Léo, primary, Bajrami, Ilirjana, primary, Dorvault, Nicolas, primary, Garrido, Marlène, primary, Meisenberg, Cornelia, primary, Lamb, Andrew, primary, Ngo, Carine, primary, Hopkins, Suzanna R., primary, Roumeliotis, Theodoros I., primary, Jouny, Samuel, primary, Hénon, Clémence, primary, Kawai-Kawachi, Asuka, primary, Astier, Clémence, primary, Konde, Asha, primary, Del Nery, Elaine, primary, Massard, Christophe, primary, Pettitt, Stephen J., primary, Margueron, Raphaël, primary, Choudhary, Jyoti S., primary, Almouzni, Geneviève, primary, Soria, Jean-Charles, primary, Deutsch, Eric, primary, Downs, Jessica A., primary, Lord, Christopher J., primary, and Postel-Vinay, Sophie, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figures from ATR Is a Therapeutic Target in Synovial Sarcoma

Author

Jones, Samuel E., primary, Fleuren, Emmy D.G., primary, Frankum, Jessica, primary, Konde, Asha, primary, Williamson, Chris T., primary, Krastev, Dragomir B., primary, Pemberton, Helen N., primary, Campbell, James, primary, Gulati, Aditi, primary, Elliott, Richard, primary, Menon, Malini, primary, Selfe, Joanna L., primary, Brough, Rachel, primary, Pettitt, Stephen J., primary, Niedzwiedz, Wojciech, primary, van der Graaf, Winette T.A., primary, Shipley, Janet, primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

48. Data from ATR Is a Therapeutic Target in Synovial Sarcoma

Author

Jones, Samuel E., primary, Fleuren, Emmy D.G., primary, Frankum, Jessica, primary, Konde, Asha, primary, Williamson, Chris T., primary, Krastev, Dragomir B., primary, Pemberton, Helen N., primary, Campbell, James, primary, Gulati, Aditi, primary, Elliott, Richard, primary, Menon, Malini, primary, Selfe, Joanna L., primary, Brough, Rachel, primary, Pettitt, Stephen J., primary, Niedzwiedz, Wojciech, primary, van der Graaf, Winette T.A., primary, Shipley, Janet, primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table 2 from ATR Is a Therapeutic Target in Synovial Sarcoma

Author

Jones, Samuel E., primary, Fleuren, Emmy D.G., primary, Frankum, Jessica, primary, Konde, Asha, primary, Williamson, Chris T., primary, Krastev, Dragomir B., primary, Pemberton, Helen N., primary, Campbell, James, primary, Gulati, Aditi, primary, Elliott, Richard, primary, Menon, Malini, primary, Selfe, Joanna L., primary, Brough, Rachel, primary, Pettitt, Stephen J., primary, Niedzwiedz, Wojciech, primary, van der Graaf, Winette T.A., primary, Shipley, Janet, primary, Ashworth, Alan, primary, and Lord, Christopher J., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

Author

Chabanon, Roman M., primary, Morel, Daphné, primary, Eychenne, Thomas, primary, Colmet-Daage, Léo, primary, Bajrami, Ilirjana, primary, Dorvault, Nicolas, primary, Garrido, Marlène, primary, Meisenberg, Cornelia, primary, Lamb, Andrew, primary, Ngo, Carine, primary, Hopkins, Suzanna R., primary, Roumeliotis, Theodoros I., primary, Jouny, Samuel, primary, Hénon, Clémence, primary, Kawai-Kawachi, Asuka, primary, Astier, Clémence, primary, Konde, Asha, primary, Del Nery, Elaine, primary, Massard, Christophe, primary, Pettitt, Stephen J., primary, Margueron, Raphaël, primary, Choudhary, Jyoti S., primary, Almouzni, Geneviève, primary, Soria, Jean-Charles, primary, Deutsch, Eric, primary, Downs, Jessica A., primary, Lord, Christopher J., primary, and Postel-Vinay, Sophie, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results